Could the antipsychotic chlorpromazine be a potential treatment for SARS-CoV-2?
作者信息
Nobile B, Durand M, Courtet P, Van de Perre P, Nagot N, Molès J P, Olié E
机构信息
Department of Emergency Psychiatry and Acute Care, CHU Montpellier, France; PSNREC, Univ Montpellier, INSERM, CHU de Montpellier, Montpellier, France.
Pathogenesis and Control of Chronic Infection, INSERM, EFS, Université de Montpellier, Montpellier, France.
出版信息
Schizophr Res. 2020 Sep;223:373-375. doi: 10.1016/j.schres.2020.07.015. Epub 2020 Jul 25.
Abstract
摘要
相似文献
1
Could the antipsychotic chlorpromazine be a potential treatment for SARS-CoV-2?抗精神病药物氯丙嗪能否成为治疗新型冠状病毒肺炎的潜在疗法？
Schizophr Res. 2020 Sep;223:373-375. doi: 10.1016/j.schres.2020.07.015. Epub 2020 Jul 25.
2
Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing.解析新型冠状病毒（SARS-CoV-2）胞吞作用以寻找新冠肺炎（COVID-19）药物再利用的方法。
FEBS J. 2020 Sep;287(17):3664-3671. doi: 10.1111/febs.15369. Epub 2020 Jun 2.
3
[Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].[氯丙嗪在新冠病毒肺炎治疗中的重新应用：恢复研究]
Encephale. 2020 Jun;46(3S):S35-S39. doi: 10.1016/j.encep.2020.04.010. Epub 2020 Apr 29.
4
Psychiatry and COVID-19: The Role of Chlorpromazine.精神病学与新冠病毒-19：氯丙嗪的作用
Can J Psychiatry. 2020 Oct;65(10):739-740. doi: 10.1177/0706743720934997. Epub 2020 Jun 15.
5
Repurposing chlorpromazine to treat COVID-19: The reCoVery study.氯丙嗪治疗 COVID-19 的再利用：reCoVery 研究。
Encephale. 2020 Jun;46(3):169-172. doi: 10.1016/j.encep.2020.05.006. Epub 2020 May 16.
6
Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.氯丙嗪抑制 SARS-CoV-2 在人细胞中的复制。
Int J Antimicrob Agents. 2021 Mar;57(3):106274. doi: 10.1016/j.ijantimicag.2020.106274. Epub 2020 Dec 30.
7
SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis.SARS-CoV-2 通过网格蛋白介导的内吞作用感染细胞。
J Biol Chem. 2021 Jan-Jun;296:100306. doi: 10.1016/j.jbc.2021.100306. Epub 2021 Jan 19.
8
Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors.使用酸化抑制剂的双重抑制机制靶向 SARS-CoV-2 进入和感染的策略。
PLoS Pathog. 2021 Jul 12;17(7):e1009706. doi: 10.1371/journal.ppat.1009706. eCollection 2021 Jul.
9
Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted.严重急性呼吸综合征冠状病毒通过网格蛋白依赖途径进入细胞质尾缺失的表达血管紧张素转换酶2的靶细胞。
J Virol. 2007 Aug;81(16):8722-9. doi: 10.1128/JVI.00253-07. Epub 2007 May 23.
10
Inhibitor analysis revealed that clathrin-mediated endocytosis is involed in cellular entry of type III grass carp reovirus.抑制剂分析表明网格蛋白介导的内吞作用参与了 III 型草鱼呼肠孤病毒的细胞进入。
Virol J. 2018 May 24;15(1):92. doi: 10.1186/s12985-018-0993-8.
引用本文的文献
1
Chlorpromazine induces hyposalivation by inhibiting muscarinic Ca signaling in salivary glands.氯丙嗪通过抑制唾液腺中的毒蕈碱型钙信号传导诱导唾液分泌减少。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 23. doi: 10.1007/s00210-025-04438-8.
2
DRaW: prediction of COVID-19 antivirals by deep learning-an objection on using matrix factorization.DRaW：深度学习预测 COVID-19 抗病毒药物——对使用矩阵分解的反对意见。
BMC Bioinformatics. 2023 Feb 15;24(1):52. doi: 10.1186/s12859-023-05181-8.
3
Current Insights and Molecular Docking Studies of the Drugs under Clinical Trial as RdRp Inhibitors in COVID-19 Treatment.在 COVID-19 治疗中作为 RdRp 抑制剂处于临床试验阶段的药物的最新研究进展和分子对接研究。
Curr Pharm Des. 2022;28(46):3677-3705. doi: 10.2174/1381612829666221107123841.
4
Chlorpromazine, a Clinically Approved Drug, Inhibits SARS-CoV-2 Nucleocapsid-Mediated Induction of IL-6 in Human Monocytes.氯丙嗪，一种临床批准的药物，抑制 SARS-CoV-2 核衣壳介导的人单核细胞中白细胞介素 6 的诱导。
Molecules. 2022 Jun 7;27(12):3651. doi: 10.3390/molecules27123651.
5
Sigma-1 Receptor Ligands Chlorpromazine and Trifluoperazine Attenuate Ca Responses in Rat Peritoneal Macrophages.西格玛-1受体配体氯丙嗪和三氟拉嗪减弱大鼠腹腔巨噬细胞中的钙反应。
Cell tissue biol. 2022;16(3):233-244. doi: 10.1134/S1990519X22030075. Epub 2022 May 27.
6
Early Neurorehabilitation and Recovery from Disorders of Consciousness After Severe COVID-19.严重 COVID-19 后意识障碍的早期神经康复和恢复。
Neurocrit Care. 2022 Apr;36(2):357-371. doi: 10.1007/s12028-021-01359-1. Epub 2021 Oct 5.
7
Psychotropics and COVID-19: An analysis of safety and prophylaxis.精神药物与 COVID-19：安全性与预防分析。
Encephale. 2021 Dec;47(6):564-588. doi: 10.1016/j.encep.2021.08.002. Epub 2021 Sep 2.
8
Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants.利用 DockThor-VS 网络服务器进行药物设计和再利用，重点关注 SARS-CoV-2 的治疗靶点及其非同义变体。
Sci Rep. 2021 Mar 10;11(1):5543. doi: 10.1038/s41598-021-84700-0.
9
Antihistamine and cationic amphiphilic drugs, old molecules as new tools against the COVID-19?抗组胺药和阳离子两亲性药物，作为对抗新冠病毒的新工具的老分子？
Med Hypotheses. 2021 Mar;148:110508. doi: 10.1016/j.mehy.2021.110508. Epub 2021 Jan 24.
10
The Large Action of Chlorpromazine: Translational and Transdisciplinary Considerations in the Face of COVID-19.氯丙嗪的重大作用：面对新冠疫情的转化与跨学科思考
Front Pharmacol. 2020 Dec 16;11:577678. doi: 10.3389/fphar.2020.577678. eCollection 2020.
本文引用的文献
1
Clomipramine Could Be Useful in Preventing Neurological Complications of SARS-CoV-2 Infection.氯米帕明可能有助于预防新型冠状病毒感染的神经并发症。
J Neuroimmune Pharmacol. 2020 Sep;15(3):347-348. doi: 10.1007/s11481-020-09939-2. Epub 2020 Jun 29.
2
[Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].[氯丙嗪在新冠病毒肺炎治疗中的重新应用：恢复研究]
Encephale. 2020 Jun;46(3S):S35-S39. doi: 10.1016/j.encep.2020.04.010. Epub 2020 Apr 29.
3
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic.正在进行的 COVID-19 大流行管理临床试验。
Trends Pharmacol Sci. 2020 Jun;41(6):363-382. doi: 10.1016/j.tips.2020.03.006. Epub 2020 Apr 9.
4
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.新型冠状病毒病中“细胞因子风暴”的发病机制与治疗。
J Infect. 2020 Jun;80(6):607-613. doi: 10.1016/j.jinf.2020.03.037. Epub 2020 Apr 10.
5
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.SARS-CoV-2 刺突糖蛋白的特征及其对病毒进入的影响，以及与 SARS-CoV 的免疫交叉反应性。
Nat Commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9.
6
MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells.中东呼吸综合征冠状病毒发病机制及已上市药物在人源单核细胞来源抗原提呈细胞中的抗病毒效果。
PLoS One. 2018 Mar 22;13(3):e0194868. doi: 10.1371/journal.pone.0194868. eCollection 2018.
7
Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.中东呼吸综合征和严重急性呼吸综合征：当前的治疗选择和新型疗法的潜在靶点。
Drugs. 2017 Dec;77(18):1935-1966. doi: 10.1007/s40265-017-0830-1.
8
Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.将临床已开发药物重新用于治疗中东呼吸综合征冠状病毒感染。
Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93. doi: 10.1128/AAC.03036-14. Epub 2014 May 19.
9
Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture.对一个经美国食品药品监督管理局批准的化合物文库进行筛选，鉴定出四种在细胞培养中可抑制中东呼吸综合征冠状病毒复制的小分子抑制剂。
Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84. doi: 10.1128/AAC.03011-14. Epub 2014 May 19.
10
Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted.严重急性呼吸综合征冠状病毒通过网格蛋白依赖途径进入细胞质尾缺失的表达血管紧张素转换酶2的靶细胞。
J Virol. 2007 Aug;81(16):8722-9. doi: 10.1128/JVI.00253-07. Epub 2007 May 23.
Zotero 插件